Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
Jawad H. Butt, Kieran F. Docherty, Pardeep S. Jhund, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 513-525
Open Access | Times Cited: 59

Showing 1-25 of 59 citing articles:

2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Isabelle C. Van Gelder, Michiel Rienstra, Karina V Bunting, et al.
European Heart Journal (2024)
Open Access | Times Cited: 361
Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction
Yogesh N.V. Reddy, Barry A. Borlaug, Bernard J. Gersh
Circulation (2022) Vol. 146, Iss. 4, pp. 339-357
Open Access | Times Cited: 78
2024 update in heart failure
Alberto Beghini, Antonio Maria Sammartino, Z. Papp, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 31
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Joshua Newman, Eileen O’Meara, Michael Böhm, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 9, pp. 932-950
Closed Access | Times Cited: 23
SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Marco Valerio Mariani, Giovanna Manzi, Nicola Pierucci, et al.
Journal of Cardiovascular Electrophysiology (2024) Vol. 35, Iss. 9, pp. 1754-1765
Closed Access | Times Cited: 23
SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta‐analysis of randomized clinical trials
Connor P. Oates, Carlos G. Santos‐Gallego, A. Smith, et al.
Journal of Cardiovascular Electrophysiology (2023) Vol. 34, Iss. 5, pp. 1277-1285
Open Access | Times Cited: 36
Treatment of type 2 diabetes patients with heart conditions
Gülali Aktaş, Burçin Meryem Atak Tel, Ramiz Tel, et al.
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 3, pp. 255-265
Closed Access | Times Cited: 31
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events
Buena Aziri, Edin Begić, Slobodan Јаnkovic, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 3, pp. 1499-1530
Open Access | Times Cited: 23
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
Gerasimos Filippatos, Dimitrios Farmakis, Javed Butler, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 970-977
Open Access | Times Cited: 22
Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
Jae-Hyun Lim, Soongu Kwak, You‐Jung Choi, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 11
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 8
Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction
Jawad H. Butt, Toru Kondo, Pardeep S. Jhund, et al.
Journal of the American College of Cardiology (2022) Vol. 80, Iss. 18, pp. 1705-1717
Open Access | Times Cited: 34
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
Hongda Zhang, Lei Ding, Lijie Mi, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 7, pp. 770-779
Closed Access | Times Cited: 20
Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity‐Score Matching Study and Meta‐Analysis
Zixu Zhao, Chao Jiang, Liu He, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 24
Open Access | Times Cited: 17
The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
Yi‐Hsin Chan, Tze‐Fan Chao, Shao‐Wei Chen, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 26
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis
Chao Li, Jie Yu, Carinna Hockham, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 10, pp. 1927-1938
Open Access | Times Cited: 22
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
SGLT2 inhibitors and the cardiac rhythm: unraveling the connections
Aritra Paul, Chadi Tabaja, Oussama M. Wazni
International Journal of Arrhythmia (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
D. A. Ishmaev, Magdalena Vasileva, D. V. Duplyakov
The Russian Archives of Internal Medicine (2025) Vol. 15, Iss. 1, pp. 17-23
Open Access
Antiarrhythmic Effects of SGLT2 Inhibitors on Supraventricular Tachyarrhythmias in Patients with HFrEF
Lyuboslav Katov, Jonas Rostan, Yannick Teumer, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 786-786
Open Access
Sex Differences in Clinical Characteristics and Management of Non-valvular Atrial Fibrillation in a Resource-Limited Setting
F. Baez, G. Mejía, Julia Ramírez, et al.
Cureus (2025)
Open Access
Implications of Heart Failure Treatment on Atrial Fibrillation Onset: A Retrospective Study
Loredana Suhov, Adrian Apostol, Larissa Dăniluc, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 414-414
Open Access
Atrial Fibrillation (AF) and Heart Failure With Preserved Ejection Fraction (HFpEF): Advances and Challenges
Sanjeev Saksena, April Slee, Ranghadham Nagarakanti, et al.
Journal of Cardiovascular Electrophysiology (2025)
Open Access
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
Qing Feng, Moya Wu, Zizhao Mai
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Finerenone and Atrial Fibrillation in Heart Failure
Shingo Matsumoto, Alasdair Henderson, Pardeep S. Jhund, et al.
JAMA Cardiology (2025)
Closed Access
Page 1 - Next Page

Scroll to top